JP2009530616A - 有核赤血球成分を含むリファレンスコントロール組成物 - Google Patents
有核赤血球成分を含むリファレンスコントロール組成物 Download PDFInfo
- Publication number
- JP2009530616A JP2009530616A JP2009500542A JP2009500542A JP2009530616A JP 2009530616 A JP2009530616 A JP 2009530616A JP 2009500542 A JP2009500542 A JP 2009500542A JP 2009500542 A JP2009500542 A JP 2009500542A JP 2009530616 A JP2009530616 A JP 2009530616A
- Authority
- JP
- Japan
- Prior art keywords
- red blood
- nucleated
- blood cells
- nucleated red
- control composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 208
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 239000013643 reference control Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 69
- 210000004369 blood Anatomy 0.000 claims abstract description 65
- 239000008280 blood Substances 0.000 claims abstract description 65
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 64
- 238000005259 measurement Methods 0.000 claims abstract description 54
- 210000000601 blood cell Anatomy 0.000 claims abstract description 49
- 210000004027 cell Anatomy 0.000 claims abstract description 46
- 210000001772 blood platelet Anatomy 0.000 claims abstract description 34
- 239000000725 suspension Substances 0.000 claims abstract description 22
- 241000283073 Equus caballus Species 0.000 claims abstract description 16
- 241001494479 Pecora Species 0.000 claims abstract description 10
- 210000001995 reticulocyte Anatomy 0.000 claims abstract description 8
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 7
- 241000282326 Felis catus Species 0.000 claims abstract description 5
- 238000000149 argon plasma sintering Methods 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 230000003278 mimic effect Effects 0.000 claims description 12
- 230000003204 osmotic effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 5
- 239000000834 fixative Substances 0.000 claims description 5
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000002847 impedance measurement Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 210000003924 normoblast Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 241000272814 Anser sp. Species 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- -1 poly (ethyleneoxy) Ethanol Polymers 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-O carboxymethyl-[3-(dodecanoylamino)propyl]-dimethylazanium Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)=O MRUAUOIMASANKQ-UHFFFAOYSA-O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 2
- 229960001083 diazolidinylurea Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001374 small-angle light scattering Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- BFHKYHMIVDBCPC-UHFFFAOYSA-N 1,3,5,7-tetrahydro-[1,3]oxazolo[3,4-c][1,3]oxazol-7a-ylmethanol Chemical compound C1OCN2COCC21CO BFHKYHMIVDBCPC-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 description 1
- GYJNVSAUBGJVLV-UHFFFAOYSA-N 3-(dimethylazaniumyl)propane-1-sulfonate Chemical compound CN(C)CCCS(O)(=O)=O GYJNVSAUBGJVLV-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 229910052936 alkali metal sulfate Inorganic materials 0.000 description 1
- 229910001617 alkaline earth metal chloride Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 description 1
- HXWGXXDEYMNGCT-UHFFFAOYSA-M decyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)C HXWGXXDEYMNGCT-UHFFFAOYSA-M 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 229960001162 dihydrostreptomycin sulfate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940075468 lauramidopropyl betaine Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108700019599 monomethylolglycine Proteins 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 210000000948 non-nucleated cell Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- XCOHAFVJQZPUKF-UHFFFAOYSA-M octyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCC[N+](C)(C)C XCOHAFVJQZPUKF-UHFFFAOYSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- QUBQYFYWUJJAAK-UHFFFAOYSA-N oxymethurea Chemical compound OCNC(=O)NCO QUBQYFYWUJJAAK-UHFFFAOYSA-N 0.000 description 1
- 229950005308 oxymethurea Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- WZJVQUUBEVDURL-UHFFFAOYSA-N pentanedial;phosphoric acid Chemical compound OP(O)(O)=O.O=CCCCC=O WZJVQUUBEVDURL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/1012—Calibrating particle analysers; References therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
- G01N15/12—Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1468—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle
- G01N15/147—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1019—Associating Coulter-counter and optical flow cytometer [OFC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本発明は、有核赤血球成分を含むリファレンスコントロール組成物ならびに血液分析器で血液サンプルの有核赤血球を決定するためのリファレンスコントロール組成物の作製方法および使用方法に関する。
品質管理は、長きにわたり臨床血液学における必要且つ日常的な手順である。種々の血球型の計数の精度は、適切なコントロール生成物の使用およびコントロール生成物の使用方法に一部依存する。装置故障の可能性が絶えず存在するので、現在利用可能な粒子計数のための多数の型の装置と共にコントロール生成物の使用による品質管理が必要である。自動粒子計数装置の品質管理プログラムの伝統的な維持方法は、全血標準として新鮮なヒト血液を提供することからなる。しかし、この新鮮な血液は1日しか使用できず、したがって、より長い製品寿命を有する種々のコントロール生成物が開発されてきた。
1つの態様では、本発明は、血液サンプルの有核赤血球を模倣するための固定非有核血球から作製した有核赤血球成分、および有核赤血球の測定のための血液分析器への成分の送達に適切な懸濁培地を含む、有核赤血球成分を含むリファレンスコントロール組成物に関する。非有核血球の天然の細胞サイズは、測定すべき血液サンプルの有核赤血球の核サイズと実質的に類似する。本発明の目的に適切な非有核血球には、ウマ、ヒツジ、ウシ、ネコ、イヌ、ブタの赤血球またはその組み合わせが含まれる。さらに、有核赤血球成分は、実質的に核酸を含まない。
1つの態様では、本発明は、有核赤血球(NRBC)成分を含むリファレンスコントロール組成物ならびに有核赤血球成分およびリファレンスコントロール組成物の調製方法を提供する。
(1)模倣すべき有核赤血球の核のサイズと実質的に類似する天然の細胞サイズを有する非有核赤血球を含む一定量の全血を採取すること、
(2)遠心分離によって他の細胞成分(白血球、血小板、および血漿芽含まれる)から非有核赤血球を分離すること、
(3)押し固めた細胞を洗浄液で洗浄すること、
(4)非有核血球を固定培地で固定すること、
(5)固定非有核血球を洗浄液で洗浄すること、および
(6)固定非有核血球を適切な懸濁培地中に懸濁して、血液分析器での分析のためのリファレンスコントロール組成物を形成すること。
リン酸緩衝化生理食塩水(PBS)
成分 量(g/l)
リン酸二水素ナトリウム: 0.2g
リン酸一水素二ナトリウム7水和物: 2.0g
アジ化ナトリウム: 0.1g
塩化ナトリウム: 9.4g
蒸留水で1Lにする: 約pH7.4
浸透圧315〜345mOsm/kgH2O
アナログ固定培地1
成分 量(g/l)
リン酸一水素二ナトリウム7水和物: 2.0g
リン酸二水素ナトリウム: 0.2g
塩化ナトリウム: 8.0g
グルタルアルデヒド(25%): 40ml
蒸留水で1Lにする: 約pH7.4
浸透圧285mOsm/kgH2O
懸濁培地1
成分 範囲(g/l) 好ましい範囲(g/l)
キサンチン化合物 1〜10 2〜7
アデノシン一リン酸 0.1〜1.0 0.2〜0.8
イノシン 0.1〜1.0 0.2〜0.8
得るのに十分なpH調整剤 pH5.8〜6.8 pH6.0〜6.5
得るのに十分な浸透圧調整剤 200〜400mOsm 250〜350
防腐剤: 有効量 2.0〜6.0
蒸留水で1Lにする
懸濁培地2
成分 好ましい範囲(g/lまたはml/l)
プロピルパラベン 0.3〜1.0g
メチルパラベン 0.5〜1.0g
塩酸プロカイン 0.1〜0.5g
デオキシコール酸 0.1〜0.9g
ラクトース 10.0〜50.0g
アクチジオン 0.1〜0.6g
クエン酸三ナトリウム無水物 3.0〜8.0g
クエン酸一水和物 0.3〜0.9g
リン酸二水素ナトリウム一水和物 0.8〜2.5mg
塩酸フェネルガン 0.1〜1.0g
コリスチメタン酸ナトリウム 0.2〜0.9g
(colistimethate,sodium)
ペニシリンG.(ナトリウム塩) 0.5×106〜3×106単位
硫酸カナマイシン 0.2〜0.8g
硫酸ネオマイシン 0.2〜1.0g
5’−AMP 0.4〜1.0g
アデニン 0.2〜0.8g
イノシン 0.4〜1.0g
硫酸ジヒドロストレプトマイシン 0.2〜1.0g
塩酸テトラサイクリン 0.2〜1.0g
30%ウシアルブミン 100〜350ml
蒸留水で1Lにする
ウマ赤血球を使用したNRBCアナログ調製のための処理工程
1.抗凝固薬を含む容器中でウマから50mlの全血を採取する。ウマ全血を遠心分離し、白血球、血小板、および血漿を含む上層を除去した。
50mlの全血をヒツジから採取し、工程3で以下に示すアナログ固定培地2を使用したこと以外は実施例1と同一の処理工程を使用して処理した。処理したヒツジ赤血球を、懸濁培地1に再懸濁して、別のNRBCリファレンスコントロール組成物を形成させた。
アナログ固定培地2
成分 量(g/l)
リン酸一水素二ナトリウム7水和物: 2.0g
リン酸二水素ナトリウム: 0.2g
塩化ナトリウム: 9.4g
グルタルアルデヒド(25%) 40ml
蒸留水で1Lにする: 約pH7.4
浸透圧320mOsm/kgH2O
(実施例3)
有核赤血球成分、白血球成分、ならびに赤血球および血小板成分を含むリファレンスコントロール組成物
調製手順:
1.所定体積の実施例1の懸濁培地1を提供する。
このリファレンスコントロール組成物の作製手順は、工程4で所定量の複数の白血球小集団アナログを、実施例1または2で作製した安定化ヒト赤血球、血小板成分、およびNRBC成分を含む懸濁培地に添加することを除き、実施例3に記載の手順と本質的に同一である。
Claims (25)
- 有核赤血球成分を含むリファレンスコントロール組成物であって、
(a)血液サンプルの有核赤血球を模倣するための固定非有核血球から作製した有核赤血球成分、および
(b)該有核赤血球の測定のための血液分析器への該成分の送達に適切な懸濁培地
を含む、リファレンスコントロール組成物。 - 前記非有核血球が、前記血液サンプルの有核赤血球の核サイズと実質的に類似する天然の細胞サイズを有する、請求項1に記載のリファレンスコントロール組成物。
- 前記非有核血球が、ウマ、ヒツジ、ウシ、ネコ、イヌ、ブタの赤血球またはその組み合わせを含む、請求項2に記載のリファレンスコントロール組成物。
- 前記固定非有核血球が実質的に核酸を含まない、請求項2に記載のリファレンスコントロール組成物。
- 白血球成分をさらに含む、請求項1に記載のリファレンスコントロール組成物。
- 赤血球成分をさらに含む、請求項1に記載のリファレンスコントロール組成物。
- 血小板成分をさらに含む、請求項1に記載のリファレンスコントロール組成物。
- 網状赤血球成分をさらに含む、請求項1に記載のリファレンスコントロール組成物。
- 有核赤血球成分を含むリファレンスコントロール組成物を作製する方法であって、
a)測定すべき有核赤血球の核のサイズと実質的に類似する天然の細胞サイズを有する非有核血球を提供する工程、
b)該非有核血球を固定培地で固定する工程、および
c)工程(b)から得た固定非有核血球を懸濁培地に懸濁して、リファレンスコントロール組成物を形成する工程
を含む、方法。 - 前記非有核血球が、ウマ、ヒツジ、ウシ、ネコ、イヌ、ブタの赤血球またはその組み合わせを含む、請求項9に記載の方法。
- 前記固定非有核血球が実質的に核酸を含まない、請求項9に記載の方法。
- 処理溶液が固定剤および浸透圧調整剤を含む、請求項9に記載の方法。
- 工程(b)の前に前記非有核血球を、該非有核血球を球形化する(sphere)ための球形化試薬(sphering reagent)と接触させる工程をさらに含む、請求項9に記載の方法。
- 白血球成分、赤血球成分、血小板成分、網状赤血球成分、またはその組み合わせを前記懸濁培地に添加する工程をさらに含む、請求項9に記載の方法。
- 有核赤血球成分を含むリファレンスコントロール組成物を使用する方法であって、
a)測定すべき血液サンプルの有核赤血球を模倣するための固定非有核血球から作製した有核赤血球成分を含むリファレンスコントロール組成物を提供する工程、
b)該血液サンプルの有核赤血球の測定に適合した血液分析器を提供する工程、
c)該リファレンスコントロール組成物を該血液分析器で分析し、該有核赤血球成分を測定する工程、および
d)該リファレンスコントロール組成物中の有核赤血球成分を報告する工程
を含む、方法。 - 前記有核赤血球成分の測定を、DCインピーダンスシグナルの測定によって行う、請求項15に記載の方法。
- 前記有核赤血球成分の測定を、光散乱シグナルの2つの角度の測定によって行う、請求項15に記載の方法。
- 前記光散乱シグナルの2つの角度が、10°未満で検出される低角度光散乱シグナルである、請求項17に記載の方法。
- 前記光散乱シグナルの2つの角度が低角度光散乱シグナルおよび中角度(medium angle)光散乱シグナルまたは直角光散乱シグナルである、請求項17に記載の方法。
- 前記有核赤血球成分の測定を、DCインピーダンスシグナルおよび光散乱シグナルの測定によって行う、請求項15に記載の方法。
- 前記有核赤血球成分の測定を、軸方向の光の損失(axial light loss)およびDCインピーダンスシグナルの測定によって行う、請求項15に記載の方法。
- 前記有核赤血球成分の測定を、軸方向の光の損失および光散乱シグナルの測定によって行う、請求項15に記載の方法。
- 前記光散乱シグナルが低角度光散乱シグナルである、請求項22に記載の方法。
- 前記光散乱シグナルが中角度光散乱シグナルである、請求項22に記載の方法。
- 前記有核赤血球成分の測定を、前記血液サンプルの第1のアリコートの第1のDCインピーダンスシグナルの測定、ならびに該血液サンプルの第2のアリコートの第2のDCインピーダンスシグナル、高周波インピーダンスシグナル、および光散乱シグナルの測定によって行う、請求項15に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/377,171 | 2006-03-16 | ||
US11/377,171 US7354767B2 (en) | 2006-03-16 | 2006-03-16 | Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells |
PCT/US2007/062670 WO2007109396A2 (en) | 2006-03-16 | 2007-02-23 | Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009530616A true JP2009530616A (ja) | 2009-08-27 |
JP4945629B2 JP4945629B2 (ja) | 2012-06-06 |
Family
ID=38518360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009500542A Active JP4945629B2 (ja) | 2006-03-16 | 2007-02-23 | 有核赤血球成分を含むリファレンスコントロール組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7354767B2 (ja) |
EP (1) | EP2002256B1 (ja) |
JP (1) | JP4945629B2 (ja) |
CN (1) | CN101400996B (ja) |
WO (1) | WO2007109396A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013522644A (ja) * | 2010-03-24 | 2013-06-13 | ベックマン コールター, インコーポレイテッド | 血液サンプルを分析するための方法およびシステム |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618821B2 (en) * | 2007-04-13 | 2009-11-17 | Streck, Inc. | Simulated blood components and methods |
CN101881778B (zh) * | 2009-05-06 | 2014-01-29 | 深圳迈瑞生物医疗电子股份有限公司 | 网织红细胞模拟物及其制备方法 |
CN102109430B (zh) | 2009-12-25 | 2013-11-06 | 深圳迈瑞生物医疗电子股份有限公司 | 有核红细胞模拟粒子,血液质控物及其制备方法和用途 |
US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
WO2012151105A2 (en) * | 2011-05-04 | 2012-11-08 | Abbott Laboratories | Basophil analysis system and method |
CN105717312B (zh) * | 2014-12-04 | 2018-07-06 | 深圳迈瑞生物医疗电子股份有限公司 | 一种红细胞模拟粒子、其制备方法以及含该模拟粒子的质控物或校准物 |
CN109142761B (zh) * | 2018-09-17 | 2022-02-18 | 迪瑞医疗科技股份有限公司 | 网织红细胞模拟物及其制备方法与应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005121661A (ja) * | 1999-08-20 | 2005-05-12 | Streck Lab Inc | マルチパラメーター血液測定用の血液学的コントロール及びシステム |
JP2005128029A (ja) * | 1995-04-28 | 2005-05-19 | Coulter Internatl Corp | 血液学的コントロール製品 |
JP2005233935A (ja) * | 2003-12-19 | 2005-09-02 | Beckman Coulter Inc | 網状赤血球及び有核赤血球の血液学的対照品 |
JP2007515623A (ja) * | 2003-10-12 | 2007-06-14 | ベックマン コールター,インコーポレイティド | 有核赤血球の測定のためのリファレンスコントロールの使用方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US640337A (en) * | 1899-10-05 | 1900-01-02 | Augustus Torrey | Dumping-car. |
US3873467A (en) * | 1974-02-01 | 1975-03-25 | United Medical Lab Inc | Hematologic reference control |
US4213876A (en) * | 1978-08-22 | 1980-07-22 | Coulter Electronics, Inc. | Multi-purpose blood diluent for use in electronic blood analysis instrumentation |
US4299726A (en) * | 1979-05-07 | 1981-11-10 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor |
US4358394A (en) * | 1979-05-07 | 1982-11-09 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability |
US4264470A (en) * | 1979-05-07 | 1981-04-28 | Coulter Electronics, Inc. | Selecting goat erythrocytes to simulate human platelets in hematologic reference controls |
US4405719A (en) * | 1981-05-29 | 1983-09-20 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures |
US4389490A (en) * | 1981-05-29 | 1983-06-21 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; and diluents thereof |
US4735504A (en) * | 1983-10-31 | 1988-04-05 | Technicon Instruments Corporation | Method and apparatus for determining the volume & index of refraction of particles |
US4704364A (en) * | 1984-05-18 | 1987-11-03 | Coulter Electronics, Inc. | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
KR970007077B1 (ko) * | 1987-03-13 | 1997-05-02 | 코울터 일렉트로닉스 인커퍼레이티드 | 광산란 기술을 이용한 다중-부분식별 분석 방법 |
AU665413B2 (en) * | 1992-02-24 | 1996-01-04 | Coulter International Corporation | Hematology control composition for leukocyte analogs; and methods for their preparation and use |
US5559037A (en) * | 1994-12-15 | 1996-09-24 | Abbott Laboratories | Method for rapid and simultaneous analysis of nucleated red blood cells |
US5879900A (en) * | 1994-12-15 | 1999-03-09 | Abbott Laboratories | Method for simultaneous analysis of cell viability, nucleated red blood cells and white blood cell differentials |
US5858790A (en) * | 1996-06-26 | 1999-01-12 | Abbott Laboratories | Hematology reference control and method of preparation |
US5874310A (en) * | 1997-11-21 | 1999-02-23 | Coulter International Corp. | Method for differentiation of nucleated red blood cells |
US5917584A (en) * | 1997-11-21 | 1999-06-29 | Coulter International Corp. | Method for differentiation of nucleated red blood cells |
US6060322A (en) * | 1998-10-20 | 2000-05-09 | Coulter International Corp. | Method for identification of reticulated cells |
US6200500B1 (en) * | 1999-08-20 | 2001-03-13 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US20020136409A1 (en) * | 2001-03-21 | 2002-09-26 | Palm, Inc. | System and method for disabling radio frequency devices |
US6448085B1 (en) * | 2001-04-13 | 2002-09-10 | Sysmex Corporation | Quality control material and calibrator for nucleated red blood cell tested on hematology analyzer |
US6569682B2 (en) * | 2001-07-27 | 2003-05-27 | Coulter International Corp. | Hematology control product with increased closed vial stability |
JP2005506525A (ja) * | 2001-07-27 | 2005-03-03 | ベックマン コールター,インコーポレーテッド | 有核赤血球の計測法の方法 |
US6472215B1 (en) * | 2001-07-27 | 2002-10-29 | Coulter International Corp. | Method of analyzing nucleated red blood cells in a blood sample |
US6410330B1 (en) * | 2001-07-27 | 2002-06-25 | Coulter International Corp. | Method for measurement of nucleated red blood cells |
US6723563B2 (en) * | 2001-12-03 | 2004-04-20 | Streck Laboratories Inc. | Hematology reference control |
US6653137B2 (en) * | 2001-12-03 | 2003-11-25 | Streck Laboratories Inc. | Hematology reference control |
US7135341B2 (en) * | 2004-04-07 | 2006-11-14 | Beckman Coulter, Inc. | Reference control containing a nucleated red blood cell component |
-
2006
- 2006-03-16 US US11/377,171 patent/US7354767B2/en active Active
-
2007
- 2007-02-23 WO PCT/US2007/062670 patent/WO2007109396A2/en active Application Filing
- 2007-02-23 CN CN2007800083229A patent/CN101400996B/zh active Active
- 2007-02-23 JP JP2009500542A patent/JP4945629B2/ja active Active
- 2007-02-23 EP EP07757394.7A patent/EP2002256B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005128029A (ja) * | 1995-04-28 | 2005-05-19 | Coulter Internatl Corp | 血液学的コントロール製品 |
JP2005121661A (ja) * | 1999-08-20 | 2005-05-12 | Streck Lab Inc | マルチパラメーター血液測定用の血液学的コントロール及びシステム |
JP2007515623A (ja) * | 2003-10-12 | 2007-06-14 | ベックマン コールター,インコーポレイティド | 有核赤血球の測定のためのリファレンスコントロールの使用方法 |
JP2005233935A (ja) * | 2003-12-19 | 2005-09-02 | Beckman Coulter Inc | 網状赤血球及び有核赤血球の血液学的対照品 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013522644A (ja) * | 2010-03-24 | 2013-06-13 | ベックマン コールター, インコーポレイテッド | 血液サンプルを分析するための方法およびシステム |
Also Published As
Publication number | Publication date |
---|---|
WO2007109396A3 (en) | 2007-11-29 |
US20070218558A1 (en) | 2007-09-20 |
EP2002256A4 (en) | 2015-07-15 |
EP2002256A2 (en) | 2008-12-17 |
JP4945629B2 (ja) | 2012-06-06 |
WO2007109396A2 (en) | 2007-09-27 |
US7354767B2 (en) | 2008-04-08 |
CN101400996A (zh) | 2009-04-01 |
EP2002256B1 (en) | 2017-10-18 |
CN101400996B (zh) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4993603B2 (ja) | 有核赤血球成分を含む参照対照 | |
JP4945629B2 (ja) | 有核赤血球成分を含むリファレンスコントロール組成物 | |
JP4549440B2 (ja) | 基準対照血液および製法 | |
EP0628166B1 (en) | Suspension media for hematological composition and method for its use | |
JP4999681B2 (ja) | 未成熟の顆粒球成分を含む血液学の参照対照 | |
US20050048656A1 (en) | Quality control method | |
US7482161B2 (en) | Preparation of a red blood cell component for a hematology control | |
JP3822625B2 (ja) | 血液学的コントロール製品 | |
US7198953B2 (en) | Method of using a reference control composition for measurement of nucleated red blood cells | |
EP1682865B1 (en) | Method of using a reference control composition for measurement of nucleated red blood cells | |
US6759246B1 (en) | Hematology control composition including lymphocyte analogs and method for preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110711 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111101 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120222 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120305 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4945629 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150309 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |